Nuformix plc (LON:NFX – Get Free Report) shares traded up 8.7% during mid-day trading on Wednesday . The stock traded as high as GBX 0.09 ($0.00) and last traded at GBX 0.09 ($0.00). 3,331,248 shares were traded during mid-day trading, a decline of 96% from the average session volume of 74,219,031 shares. The stock had previously closed at GBX 0.08 ($0.00).
Nuformix Stock Performance
The stock has a market cap of £1.02 million, a PE ratio of -2.52 and a beta of 1.22. The firm has a 50-day moving average price of GBX 0.07 and a 200-day moving average price of GBX 0.09.
Nuformix (LON:NFX – Get Free Report) last issued its earnings results on Wednesday, January 29th. The company reported GBX (0.46) (($0.01)) earnings per share (EPS) for the quarter.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Read More
- Five stocks we like better than Nuformix
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Alphabet’s Pullback Just Opened a Window for Smart Investors
- What does consumer price index measure?
- Moderna: A Generational Opportunity for Investors in 2025
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Buffett Just Dumped His S&P 500 Holdings—What It Means for You
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
